Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, California 92093, United States.
J Am Chem Soc. 2024 Mar 20;146(11):7708-7722. doi: 10.1021/jacs.3c14490. Epub 2024 Mar 8.
Developing new antibiotics and delivery strategies is of critical importance for treating infections caused by Gram-negative bacterial pathogens. Hijacking bacterial iron uptake machinery, such as that of the siderophore enterobactin (Ent), represents one promising approach toward these goals. Here, we report a novel Ent-inspired siderophore-antibiotic conjugate (SAC) employing an alternative siderophore moiety as the delivery vector and demonstrate the potency of our SACs harboring the β-lactam antibiotic ampicillin (Amp) against multiple pathogenic Gram-negative bacterial strains. We establish the ability of -(nitrilotris(ethane-2,1-diyl))tris(2,3-dihydroxybenzamide) (TRENCAM, hereafter TC), a synthetic mimic of Ent, to facilitate drug delivery across the outer membrane (OM) of Gram-negative pathogens. Conjugation of Amp to a new monofunctionalized TC scaffold affords TC-Amp, which displays markedly enhanced antibacterial activity against the gastrointestinal pathogen serovar Typhimurium (Tm) compared with unmodified Amp. Bacterial uptake, antibiotic susceptibility, and microscopy studies with Tm show that the TC moiety facilitates TC-Amp uptake by the OM receptors FepA and IroN and that the Amp warhead inhibits penicillin-binding proteins. Moreover, TC-Amp achieves targeted activity, selectively killing Tm in the presence of a commensal lactobacillus. Remarkably, we uncover that TC-Amp and its Ent-based predecessor Ent-Amp achieve enhanced antibacterial activity against diverse Gram-negative ESKAPE pathogens that express Ent uptake machinery, including strains that possess intrinsic β-lactam resistance. TC-Amp and Ent-Amp exhibit potency comparable to that of the FDA-approved SAC cefiderocol against Gram-negative pathogens. These results demonstrate the effective application of native and appropriately designed nonnative siderophores as vectors for drug delivery across the OM of multiple Gram-negative bacterial pathogens.
开发新的抗生素和输送策略对于治疗革兰氏阴性细菌病原体引起的感染至关重要。劫持细菌铁摄取机制,例如细菌铁载体(Ent)的摄取机制,是实现这些目标的一种很有前途的方法。在这里,我们报告了一种新的 Ent 启发式铁载体-抗生素缀合物(SAC),该缀合物采用替代的铁载体部分作为输送载体,并证明了我们的 SAC 携带β-内酰胺抗生素氨苄西林(Amp)对多种致病性革兰氏阴性细菌菌株的效力。我们确定了 -(亚硝三(乙二胺)三(2,3-二羟基苯甲酰胺)(TRENCAM,以下简称 TC)的能力,TC 是 Ent 的合成模拟物,能够促进药物穿过革兰氏阴性病原体的外膜(OM)。将 Amp 与新的单官能化 TC 支架缀合可得到 TC-Amp,与未修饰的 Amp 相比,TC-Amp 对胃肠道病原体血清型 Typhimurium(Tm)的抗菌活性明显增强。与未修饰的 Amp 相比,用 TC 部分促进 Tm 中 TC-Amp 的摄取,用 TC 部分促进 Tm 中 TC-Amp 的摄取。细菌摄取、抗生素敏感性和 Tm 的显微镜研究表明,TC 部分促进了 OM 受体 FepA 和 IroN 的 TC-Amp 摄取,并且 Amp 弹头抑制了青霉素结合蛋白。此外,TC-Amp 可实现靶向活性,在共生乳杆菌存在的情况下选择性杀死 Tm。值得注意的是,我们发现 TC-Amp 和它的 Ent 前体 Ent-Amp 对表达 Ent 摄取机制的多种革兰氏阴性 ESKAPE 病原体(包括具有固有β-内酰胺耐药性的菌株)表现出增强的抗菌活性。TC-Amp 和 Ent-Amp 的效力可与 FDA 批准的 SAC 头孢地尔唑相媲美。这些结果表明,天然和适当设计的非天然铁载体可作为多种革兰氏阴性细菌病原体 OM 药物输送的载体有效应用。